|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000187678 |
Summary for SPRY4 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000187678 | Gene symbol | SPRY4 |
| Gene name | sprouty RTK signaling antagonist 4 | |
| HGNC | 15533 | |
| Entrez ID | 81848 | |
| Gene type | protein_coding | |
| Synonyms | SPRY4| | |
| UniProtAcc | Q9C004 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SPRY4 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SPRY4 | 1.83e+03 | 1.11e+00 | 1.42e-01 | 7.82e+00 | 5.30e-15 | 5.20e-14 | COAD |
| SPRY4 | 1.87e+03 | 1.10e+00 | 2.17e-01 | 5.09e+00 | 3.53e-07 | 3.54e-06 | READ |
Top |
Sex-biased somatic mutation for SPRY4 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SPRY4 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg08951638 | chr5:142326648 | CGI:chr5:142325826-142326123 | promoter | 3.41e-01 | 2.19e-01 | 2.54e+00 | 1.10e-02 | 2.77e-02 | 1.22e-01 |
| ACC | cg08951638 | chr5:142326648 | CGI:chr5:142325826-142326123 | promoter | 3.88e-01 | 5.29e-01 | -2.56e+00 | 1.05e-02 | 2.61e-02 | -1.41e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg08951638 | chr5:142326648 | CGI:chr5:142325826-142326123 | promoter | 3.96e-01 | 5.33e-01 | -4.12e+00 | 3.78e-05 | 1.25e-04 | -1.37e-01 |
| HNSC | cg14619259 | chr5:142325974 | CGI:chr5:142325826-142326123 | promoter,gene body | 1.50e-01 | 3.02e-02 | 2.55e+00 | 1.09e-02 | 1.38e-02 | 1.20e-01 |
| LIHC | cg14619259 | chr5:142325974 | CGI:chr5:142325826-142326123 | promoter,gene body | 4.21e-01 | 2.28e-01 | 2.56e+00 | 1.04e-02 | 1.26e-02 | 1.92e-01 |
| LIHC | cg24393055 | chr5:142325956 | CGI:chr5:142325826-142326123 | promoter,gene body | 3.03e-01 | 1.82e-01 | 1.98e+00 | 4.71e-02 | 4.75e-02 | 1.22e-01 |
| CHOL | cg14619259 | chr5:142325974 | CGI:chr5:142325826-142326123 | promoter,gene body | 2.89e-02 | 3.22e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -2.94e-01 |
| CHOL | cg24393055 | chr5:142325956 | CGI:chr5:142325826-142326123 | promoter,gene body | 6.66e-02 | 2.05e-01 | -3.46e+00 | 5.30e-04 | 8.63e-03 | -1.38e-01 |
| CHOL | cg08951638 | chr5:142326648 | CGI:chr5:142325826-142326123 | promoter | 3.27e-01 | 7.36e-01 | -3.10e+00 | 1.96e-03 | 1.07e-02 | -4.09e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg08951638 | chr5:142326648 | CGI:chr5:142325826-142326123 | promoter | 3.41e-01 | 4.56e-01 | -7.60e+00 | 3.07e-14 | 1.06e-13 | -1.15e-01 |
Top |
Exon skipping events with PSI in TCGA for SPRY4 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SPRY4 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SPRY4 |
| TFs related to SPRY4. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SPRY4 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SPRY4 |
| RBPs related to ES in SPRY4. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SPRY4 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs139878628 | chr5:150719005:A:C | - | 0.162001126818732 | 1.09372354355859e-08 | SARC | Female-baised eQTL |
| rs201747621 | chr5:150747083:C:T | - | 0.128133576959064 | 0.0173687829127047 | SARC | Female-baised eQTL |
| rs199753234 | chr5:150747112:T:G | - | 0.128133576959064 | 0.0173687829127047 | SARC | Female-baised eQTL |
| rs74294165 | chr5:150725230:G:A | - | 0.127950704373046 | 0.0257661351745888 | SARC | Female-baised eQTL |
| rs74369413 | chr5:150727447:T:G | - | 0.127950704373046 | 0.0257661351745888 | SARC | Female-baised eQTL |
| rs12653281 | chr5:150738441:G:C | - | 0.127950704373046 | 0.0257661351745888 | SARC | Female-baised eQTL |
| rs7446083 | chr5:150738662:C:T | - | 0.127950704373046 | 0.0257661351745888 | SARC | Female-baised eQTL |
| rs2278395 | chr5:150758634:C:A | - | 0.118799809766009 | 0.0362657103439163 | SARC | Female-baised eQTL |
| rs12659859 | chr5:150770485:G:A | - | 0.118799809766009 | 0.0362657103439163 | SARC | Female-baised eQTL |
| rs112861045 | chr5:150772324:G:A | - | 0.118799809766009 | 0.0362657103439163 | SARC | Female-baised eQTL |
| rs80321510 | chr5:150750414:G:A | - | 0.118725028955818 | 0.0368828236482761 | SARC | Female-baised eQTL |
| rs6863933 | chr5:151633913:A:G | - | 0.097689047478976 | 0.0488826241694407 | SARC | Female-baised eQTL |
| rs17097520 | chr5:141736321:G:C | - | 0.419819821168425 | 0.0412796162741911 | KIRP | Female-baised eQTL |
| rs75659722 | chr5:141741493:A:G | - | 0.419819821168425 | 0.0412796162741911 | KIRP | Female-baised eQTL |
| rs76049714 | chr5:141743131:T:C | - | 0.419819821168425 | 0.0412796162741911 | KIRP | Female-baised eQTL |
| rs144856482 | chr5:141738595:T:G | - | 0.418371011304649 | 0.0434851078593836 | KIRP | Female-baised eQTL |
| rs17097525 | chr5:141740392:C:T | - | 0.418371011304649 | 0.0434851078593836 | KIRP | Female-baised eQTL |
| rs75167827 | chr5:141740406:G:A | - | 0.418371011304649 | 0.0434851078593836 | KIRP | Female-baised eQTL |
| rs7735780 | chr5:139617842:C:A | - | 0.23299688859681 | 0.0498548375256481 | KIRP | Female-baised eQTL |
| rs27426 | chr5:135880847:C:T | - | 0.144130989730269 | 0.043319460455963 | LUSC | Female-baised eQTL |
| rs35341726 | chr5:150024616:G:T | - | 0.0993383287081414 | 0.0320058860192243 | LGG | Female-baised eQTL |
| rs79313199 | chr5:150017874:C:T | - | 0.0984889416348065 | 0.0355535372646652 | LGG | Female-baised eQTL |
| rs13178760 | chr5:150044945:C:T | - | 0.0966265608844917 | 0.0401431876701999 | LGG | Female-baised eQTL |
| rs11959916 | chr5:147161054:C:T | - | 0.103016277725542 | 0.00624107115287165 | BLCA | Female-baised eQTL |
| rs2400244 | chr5:147159227:A:T | - | 0.10308433595509 | 0.00646980910543715 | BLCA | Female-baised eQTL |
| rs6872906 | chr5:147163207:C:T | - | 0.10308433595509 | 0.00646980910543715 | BLCA | Female-baised eQTL |
| rs6872936 | chr5:147163268:C:T | - | 0.10308433595509 | 0.00646980910543715 | BLCA | Female-baised eQTL |
| rs6863126 | chr5:147164067:T:C | - | 0.10308433595509 | 0.00646980910543715 | BLCA | Female-baised eQTL |
| rs10491404 | chr5:147165893:C:T | - | 0.102325290956375 | 0.0146805702814304 | BLCA | Female-baised eQTL |
| rs12657918 | chr5:147171345:G:T | - | 0.0998187274049537 | 0.0166027042757667 | BLCA | Female-baised eQTL |
| rs79961103 | chr5:147160055:G:A | - | 0.0951819182748554 | 0.0180049788043918 | BLCA | Female-baised eQTL |
| rs11958839 | chr5:147159575:C:T | - | 0.0946811337261518 | 0.0199605181840179 | BLCA | Female-baised eQTL |
| rs66475428 | chr5:136386840:T:C | - | 0.035096286937161 | 0.0185742309163844 | LUAD | Female-baised eQTL |
| rs66464875 | chr5:136388826:C:A | - | 0.035096286937161 | 0.0185742309163844 | LUAD | Female-baised eQTL |
| rs1499774 | chr5:136374453:C:G | - | 0.0339703159777898 | 0.0249829978795614 | LUAD | Female-baised eQTL |
| rs11748766 | chr5:136319448:T:C | - | 0.0324140246026347 | 0.034632532408744 | LUAD | Female-baised eQTL |
| rs7728335 | chr5:151596010:A:G | - | 0.0451277021756228 | 0.00472454630695618 | COAD | Female-baised eQTL |
| rs7728183 | chr5:134458439:T:A | - | 0.0445795699422143 | 0.00782604876790246 | COAD | Female-baised eQTL |
| rs7729398 | chr5:151596479:G:C | - | 0.0423860127444281 | 0.0144481244035756 | COAD | Female-baised eQTL |
| rs312520 | chr5:144037865:C:T | - | 0.0531519873482267 | 0.0330977931447218 | COAD | Female-baised eQTL |
| rs312521 | chr5:144037976:A:T | - | 0.0531519873482267 | 0.0330977931447218 | COAD | Female-baised eQTL |
| rs312522 | chr5:144038122:C:G | - | 0.0531519873482267 | 0.0330977931447218 | COAD | Female-baised eQTL |
| rs1042717 | chr5:148827083:G:A | - | 0.046680796301905 | 0.0336931207397964 | COAD | Female-baised eQTL |
| rs1947582 | chr5:149512532:C:T | - | 0.0424914160628593 | 0.0488377278094 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs17723143 | chr5:149283072:G:C | - | 0.0456089115762346 | 0.0250971338147443 | BLCA | Male-baised eQTL |
| rs154100 | chr5:152109163:G:C | - | 0.0565494517806358 | 0.0304625995478655 | LUAD | Male-baised eQTL |
| rs29841 | chr5:152124666:T:C | - | 0.0527776022972358 | 0.0475210786422426 | LUAD | Male-baised eQTL |
| rs1530419 | chr5:146648977:A:C | - | -0.0428921484851312 | 0.0229941056066573 | COAD | Male-baised eQTL |
| rs10053530 | chr5:148478608:C:T | - | 0.0589864346299278 | 0.0327296924115208 | COAD | Male-baised eQTL |
| rs7729798 | chr5:146649817:T:C | - | -0.0407929012761566 | 0.033827964044755 | COAD | Male-baised eQTL |
| rs1434644 | chr5:137270396:T:C | - | 0.0322329787326412 | 0.0341330344909733 | COAD | Male-baised eQTL |
| rs1434646 | chr5:137270655:T:C | - | 0.031317938096955 | 0.0357215393311709 | COAD | Male-baised eQTL |
| rs3764930 | chr5:148125553:G:A | - | -0.0318530535959731 | 0.0388804628323311 | COAD | Male-baised eQTL |
| rs1434643 | chr5:137269568:C:T | - | 0.0316148152827786 | 0.0406881041617608 | COAD | Male-baised eQTL |
| rs2060426 | chr5:137269732:A:G | - | 0.0316148152827786 | 0.0406881041617608 | COAD | Male-baised eQTL |
| rs1434645 | chr5:137270624:G:A | - | 0.0316148152827786 | 0.0406881041617608 | COAD | Male-baised eQTL |
| rs4434375 | chr5:137003458:T:G | - | -0.0436012443444625 | 0.041771824013505 | COAD | Male-baised eQTL |
| rs2961632 | chr5:137305186:A:G | - | 0.0308851476394985 | 0.0448232364845419 | COAD | Male-baised eQTL |
| rs159576 | chr5:152103399:G:A | - | -0.0382823569763949 | 0.0453080553777891 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000187678 |
| CpG Site: cg24029050 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: - | |
| Female Effect: -0.462356921503398 | |
 | Gene ID: ENSG00000187678 |
| CpG Site: cg02713162 | |
| Position to Gene: gene | |
| Male Effect: -0.302109556859773 | |
| Female Effect: - | |
 | Gene ID: ENSG00000187678 |
| CpG Site: cg02731554 | |
| Position to Gene: gene,exon,CDS | |
| Male Effect: -0.477001814192567 | |
| Female Effect: - | |
 | Gene ID: ENSG00000187678 |
| CpG Site: cg24029050 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: -0.233486554567074 | |
| Female Effect: - | |
 | Gene ID: ENSG00000187678 |
| CpG Site: cg13305415 | |
| Position to Gene: gene | |
| Male Effect: -0.124995968268582 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg02713162 | chr5:142322808 | gene | -0.302109556859773 | 1.79088654821549e-14 | -0.48324487481623324 | 2.5338393411476097e-17 | LUSC |
| cg02731554 | chr5:142314668 | gene,exon,CDS | -0.477001814192567 | 1.34247143296084e-55 | -0.7671440826301945 | 2.240878246121681e-60 | BLCA |
| cg24029050 | chr5:142311996 | gene,exon,UTR | -0.233486554567074 | 4.28919790089359e-20 | -0.531489646223799 | 1.2318539591406425e-23 | BLCA |
| cg13305415 | chr5:142317899 | gene | -0.124995968268582 | 3.10431462450679e-13 | -0.44832317052934967 | 1.738360456453795e-16 | BLCA |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg24029050 | chr5:142311996 | gene,exon,UTR | -0.462356921503398 | 1.08516743977971e-34 | -0.7045008341648958 | 1.4885807023810693e-39 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SPRY4 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000187678 | SPRY4 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| ENSG00000187678 | SPRY4 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| ENSG00000187678 | SPRY4 | C0342384 | Idiopathic hypogonadotropic hypogonadism | 1 | CTD_human |
| ENSG00000187678 | SPRY4 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| ENSG00000187678 | SPRY4 | C3808971 | HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA | 1 | CTD_human |
